Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
Ann Oncol. 2023;34(1):33-47.
C. Sessa, J. Balmaña, S.L. Bober, et al, on behalf of the ESMO Guidelines Committee
- This guideline provides recommendations for risk-reduction and screening for individuals with a hereditary breast and ovarian cancer syndrome.
- This guideline focuses on risk-reduction and screening mainly in unaffected carriers and particularly in high-resource settings.
- The panel encompasses an international multidisciplinary group of experts.
- Recommendations are based on available scientific data and the authors’ collective expert opinion.